NL-OMON34838RecruitingNot Applicable
Pilot study: clinical evaluation of biomarkers as predictors of survival in castrate-resistant prostate cancer patients. - BOSS - Biomarker Overall Survival Study in CRPC patients
niversitair Medisch Centrum Sint Radboud0 sites50 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18 to 99 (—)
Inclusion Criteria
- •1. Histologically confirmed prostate cancer
- •2. Either biological recurrence (2 consecutive increases in the PSA level after the nadir, with a
- •minimum 2 week interval between measurements) and/or radiological recurrence (new
- •osseous lesions and/or new or enlarged soft tissue metastases)
- •3. Testosterone <50 ng/mL
- •4. PSA >5 ng/mL
- •5. ECOG performance status of 0-2
- •6. Starting first course docetaxel-based chemotherapy treatment
Exclusion Criteria
- •Within 4 wk of entry use of an antiandrogen (6wk for nilutamide and bicalutamide).
- •Within 30 days of entry radiation or radionuclide therapy.
Investigators
Similar Trials
Recruiting
Not Applicable
A biomarker assessment study to investigate the influence of high-frequency chest wall oscillations on the clearance of cerebrospinal fluid biomarkersNL-OMON51372Centre for Human Drug Research34
Recruiting
Not Applicable
Clinical research for biomarkers in patients with drug-induced lung injury and their clinical significanceCases of suspected drug-induced lung injury and performed bronchoalveolar lavage for diagnosticJPRN-UMIN000033951niversity of Occupational and Environmental Health, Department of Respiratory Medicine60
Recruiting
Not Applicable
Validation for clinical utility of biomarkers for the early diagnosis of breast cancerKCT0005212Seoul National University Hospital496
Completed
Phase 4
A non-interventional biomarker study in patients with NSCLC of adenocarcinoma tumour histology eligible for treatment with Vargatef according to the approved labelNon small-cell lung carcinoma10029107lung cancerNL-OMON46049Boehringer Ingelheim34
Recruiting
Not Applicable
An observational study to determine biomarkers for prognosis of lung lesions in patients with polymyositis/dermatomyositis complicated by interstitial lung diseasePolymyositis/dermatomyositis complicated with interstitial lung disease (PM/DM-ILD)JPRN-UMIN000046198agasaki University125